Coverage
-
October 29, 2026
Artificial intelligence-powered pharmaceutical group BioXcel has asked a Delaware bankruptcy judge to sign off on a $9.75 million settlement between the debtor and plaintiffs in a securities class action against it, saying the agreement will put one of the company's more important prepetition liabilities to bed.
8 other articles on this case.
View all »